Management of STEMI with Ticagrelor and Heparin

Introduction to Dual Antithrombotic Therapy

• The European Society of Cardiology recommends the use of ticagrelor and heparin in STEMI patients undergoing primary PCI to address two distinct but complementary thrombotic mechanisms, with the goal of reducing mortality and preventing stent thrombosis 1, 2
• The combination of anticoagulation (heparin) and antiplatelet therapy (ticagrelor) is essential for preventing thrombin generation and fibrin formation, as well as blocking ADP-mediated platelet activation and aggregation 1, 2

Guideline-Mandated Approach for Primary PCI

• The European Society of Cardiology guidelines state that anticoagulants and dual antiplatelet therapy (DAPT) are the cornerstone of pharmacological management in acute STEMI, with unfractionated heparin being the recommended anticoagulant for primary PCI 1, 2
• A loading dose of ticagrelor (or prasugrel) plus aspirin should be administered as soon as possible, with this combination being a Class I recommendation, meaning it is indicated for all patients without contraindications 1, 2

Heparin Administration During Primary PCI

• Unfractionated heparin dosing during PCI requires weight-based adjustment, with a target activated clotting time (ACT) of 250-300 seconds (HemoTec) or 300-350 seconds (Hemochron) when no GP IIb/IIIa inhibitor is planned 1, 2, 3
• Heparin should be continued through PCI and for the duration of hospitalization as clinically indicated 1, 2, 3

Critical Timing Considerations

• The European Society of Cardiology recommends administering ticagrelor loading dose (180 mg) as early as possible, ideally in the ambulance or emergency department before catheterization, and initiating heparin immediately upon STEMI diagnosis and continuing throughout the PCI procedure 1, 2

Maintenance Therapy After PCI

• The European Society of Cardiology recommends continuing ticagrelor 90 mg twice daily for 12 months (Class I recommendation), discontinuing heparin after PCI completion once hemostasis is achieved, and maintaining aspirin 75-100 mg daily indefinitely 1, 2

Common Pitfalls to Avoid

• The American Heart Association advises against using fondaparinux alone during PCI as it increases catheter thrombosis risk and requires additional UFH, and against switching between enoxaparin and UFH during the acute phase, as this increases bleeding risk 3, 5
• The European Society of Cardiology recommends against using clopidogrel instead of ticagrelor for primary PCI, as clopidogrel is reserved for fibrinolysis patients, while ticagrelor/prasugrel are preferred for primary PCI 1, 2